An alternative method of evaluating the toxicology of a chemical is to use cultured mammalian cells in a novel cell culture analogue reactor (CCA) together with a corresponding physiologically based pharmacokinetic model (PBPK). The PBPK is a mathematical model that divides the body into compartments representing organs, integrating the kinetic, thermodynamic, and anatomical parameters of the animal. The bioreactor is a physical replica of the PBPK; where the PBPK specifies an organ or tissue compartment, the bioreactor contains compartments with a corresponding cell type. The device is a continuous, dynamic system composed of multiple cell types that interact through a common circulating cell culture medium. The bioreactor and the model are coupled to evaluate the plausibility of the molecular mechanism that is input into the model. This concept is tested with naphthalene as a model of PAH (polycyclic aromatic hydrocarbons) toxicants. Two physically different CCA reactors were tested with naphthalene, and different results were observed. In the prototype system using cells attached to glass dilution bottles, naphthalene dosing resulted in generation of a circulating metabolite from the "liver" compartment (based on H4IIE cells from a rat hepatoma) that caused cell death in the "lung" compartment (L2 cells from a rat lung), as well as depletion of glutathione in the L2 cells. An improved CCA using packed bed reactors of microcarrier cultured cells did not show differences between naphthalene-dosed and nondosed controls. To explain the different responses of the two CCA designs, PBPKs of the two reactors were tested with variations in physical and kinetic parameters, and toxic mechanism. When the toxic metabolite of naphthalene was naphthoquinone rather than naphthalene epoxide as initially assumed, the PBPK results were consistent with the results of the two CCA designs. This result indicates that the mechanism of naphthalene toxicity in the CCAs may be mediated through naphthoquinone formation. The CCA-PBPK concept is demonstrated to be applicable to the study of toxic mechanisms. In particular, use of this approach suggests that in vitro naphthalene toxicity is mediated through the naphthoquinone metabolite.
Introduction
The objective of this paper is to describe and contrast the results of two cell culture analogue (CCA) devices and their corresponding physiologically based pharmacokinetic (PBPK) models to probe the molecular level mechanisms of toxicity. The CCA-PBPK approach to toxicity testing has been discussed elsewhere (2, 3) . A cell culture analogue is a direct physical replica of a physiologically based pharmacokinetic model, a mathematical model that divides the body into compartments usually corresponding to organs. The concept is depicted schematically in Figure 1 . Kinetic and thermodynamic equations can be written for each compartment that describe the fate of a chemical in that organ. A cell culture analogue of a PBPK can be constructed where the compartments indicated in the PBPK flow diagram are replaced by a biological system that contains the key reactions corresponding to the kinetic equations in the PBPK. The compartments in the CCA are connected by cell culture medium that acts as a blood surrogate, enabling interaction of the "organ" compartments. In the prototype and second generation CCA used here only a single cell type is used in each "organ", and thus these early models do not depict the full range of metabolism in the actual organ or organ architecture. However, the "organ" compartments contain the key enzymes in the PBPK model. The CCA has advantages over other in vitro systems in that it is an integrated dynamic system allowing realistic dose exposures and measurement of response.
Naphthalene has been selected as a model compound for proof-of concept studies: naphthalene metabolism is representative of a broad range of nonnutritive polycyclic aromatic hydrocarbons.
Naphthalene can be absorbed orally, by inhalation, or through the skin. Acute toxicity studies indicate that naphthalene has an oral LD 50 of 350 mg/kg in the mouse and an oral LD 50 of 2200 mg/kg in the rat (5) . The nonciliated bronchiolar epithelial cell (Clara cell) of the lung appears to be the primary target of naphthalene toxicity in mice.
Naphthalene is metabolized in the body by the cytochrome P450 monooxygenase system (CYP450) into reactive metabolites (6) . The primary site of naphthalene metabolism is the liver, where it is metabolized into naphthalene oxide enantiomers. The lung contains lower levels of monooxygenase activity overall compared to other tissues, but that activity is highly localized in the Clara cell, which may partially explain why the Clara cell is susceptible to naphthalene-induced damage. Naphthalene oxide can subsequently undergo several competing reactions: conjugation to glutathione (GSH) by glutathione transferase, hydration to dihydrodiol by epoxide hydrolase enzymes, spontaneous rearrangement to form 1-naphthol, or covalent binding to proteins (7) . Naphthol, formed from naphthalene epoxides, can be enzymatically (CYP450 isoforms) converted to naphthoquinones, reactive metabolites that are also capable of binding to proteins. Reactive metabolites produced in the liver may circulate to other organs, including the lung, to produce a toxic effect. Binding of reactive metabolites (naphthalene epoxides or naphthoquinones) is thought to be the event that leads to cellular injury. The pathway of naphthalene biotransformation in mammalian species is shown in Figure 2 .
A prototype cell culture analogue to a PBPK was previously developed and tested with naphthalene (2, 11) . However, use of the prototype device was limited as a result of design and operational constraints. In the prototype CCA cells were cultured as a monolayer on the surface of two glass bottles, representing a lung compartment (with L2 cells) and a liver compartment (H4IIE cells). The bottles were arranged in a physiological configuration, with medium circulating between the compartments. A 300 mg/kg dose of naphthalene (dissolved in methanol), administered to the reactor 30 min after the beginning of operation, resulted in a depletion of intracellular gluathione in the L2 cells in the lung chamber 6 h after dosing. The cells in the liver chamber did not show a comparable glutathione depletion at the same time point. Experiments that were 4 h in duration showed some depletion in liver cell glutathione. These results are consistent with in vivo naphthalene exposure experiments, where glutathione is depleted and then rebounds to its initial level at 6 h as a result of glutathione resynthesis (6) . Controls for the experiments were flasks of the same cell types prepared in the same way as cells in the reactor but kept in an incubator during the reactor run.
Another indicator of naphthalene toxicity is cell death, as measured by release of lactate dehydrogenase enzyme from the cells to the medium. Reactors dosed with naphthalene showed increases of LDH release to the medium that were 6% and 25% greater than reactors operated without naphthalene dosing. This indicates an increase in cell death due to naphthalene dosing. Controls using combinations of "liver"-blank, "lung"-"lung", and blank-"lung" demonstrated that a circulating naphthalene metabolite was generated in the "liver" (H4IIE cells) that circulated to the "lung" compartment and caused L2 cell death.
The CCA reactor design was revised to improve on the limitations of the prototype (see companion paper, 8). In the revised CCA the individual "organ" compartments consist of cells cultured on microcarrier beads instead of as a monolayer, permitting a higher density of cells, more realistic lung:liver cell ratio, and shorter medium residence times. The beads form a packed bed in each compartment, with medium perfusing through the compartments. Results of naphthalene dosing experiments using the packed bed CCA are described in this paper for comparison to the prototype system. PBPK models for naphthalene have been developed (9) (10) (11) (12) . These models describe the distribution and metabolism of naphthalene in the mouse, rat, and CCA reactor (12) . The PBPK of the CCA reactor developed by Quick is modified and used here to explain results from the CCA reactor itself. This PBPK is a simplified version of a rat PBPK for naphthalene, describing the distribution and metabolism of naphthalene in a three-compartment reactor (lung, liver, and other tissues) with the appropriate cell type on microcarrier beads. A corresponding PBPK of the prototype configuration, using the same kinetic and thermodynamic parameters as the packed bed PBPK, has also been written and used for comparison of the two reactor configurations.
A feature of the overall toxicology approach discussed here and initiated in Sweeney (11) is the use of a cell culture analogue reactor in tandem with a PBPK model of the system. Both the PBPK model and the CCA system are simplifications of an animal, and the model is made to be a mathematical representation of the CCA. The model and CCA are to be used together to identify discrepancies between model predictions and CCA results and then to determine which features of the model are responsible for discrepancies. To write a PBPK model one must make a number of assumptions: a mechanism of toxicity for the compound; kinetic parameters for the reactions in each step of the metabolic pathway of the compound; thermodynamic parameters that describe the way the compound and its metabolites distribute among the phases in the organ or cells; and anatomical parameters describing the organ sizes, blood flow rates, and blood residence times. If all other parameters in the model accurately reflect the CCA (kinetic and mass transfer parameters), then the hypothesized mechanisms can be tested for consistency with CCA results. If the results are inconsistent then the proposed mechanism must be reformulated.
The strength of using a PBPK directly with the CCA is illustrated by using the model to understand why results of the experiments with the two CCA reactor designs differ.
Materials and Methods
Cell Culture. The rat hepatoma cell line (H4IIE) and rat lung cell line (L2) were used in the CCA. The methods for maintenance culture are described elsewhere (2, 8, 13) . Rationale for using these cell types and culture and preparation of the cells on microcarrier beads for use in the packed bed bioreactor is described elsewhere (8, 14) .
Analyses. The toxicity endpoints measured were intracellular glutathione and leakage of lactate dehydrogenase to the extracellular medium. Reduced glutathione (GSH) was measured by a colorimetric assay based on the method of Sedlak and Lindsay (15) . Lactate dehydrogenase (LDH) was measured by colorimetric assay on a Shimadzu UV160U spectrophotometer (Columbia, MD), using a commercially available kit from Sigma, following Sigma procedure no. 500. Samples were prepared differently depending on the type of cell culture (microcarrier or monolayer) (see also 2, 8, 13) .
Measurement of Cytochrome P450 Activity. The presence of enzymes cytochrome P450IA1 and IIB1 are inferred from the enzymatic dealkylation of ethoxyresorufin and pentoxyresorufin to resorufin (respectively) that is measured fluorometrically by the method of Burke and Mayer (16) .
Sample and substrate were added to the reaction buffer (0.1 M potassium phosphate), and the reaction was initiated by the addition of nicotinamide adenine dinucleotide phosphate (NADPH). An increase in fluorescence intensity with time was measured at an excitation wavelength of 510 nm and an emission wavelength of 586 nm on an AMINCO Bowman Series 2 luminescence spectrometer (SLM-Aminco, Urbana, IL) at a temperature of 30°C. Fluorescence intensity is linear with resorufin concentration, and the activity of cytochrome P450 is calculated as pmol resorufin formed/min.
Prototype Reactor Operating Protocol. The prototype CCA reactor was operated with H4IIE cells in the liver compartment, L2 cells in the lung compartment, and a cell-free "other tissues" compartment. These experiments are described elsewhere in detail (2) and are summarized here. Cell cultures were initiated in glass milk dilution bottles 3 days prior to use in experiments. Two bottles of each cell type were initiated. The surface area of the bottles was 40 cm 2 , and the bottles were closed with foam closures.
Immediately prior to experiment, the growth medium appropriate for each cell was removed from each bottle and the cells were rinsed twice with phosphate buffered saline (PBS). Reactor operating medium, LHC-8 (Biofluids, Rockville, MD) was added to the bottles.
The bottles and reaction beaker were attached according to the configuration depicted in Figure 3 , while control bottles with cells were placed in the incubator. The pumps were started, and the flow was adjusted until the desired flow rates were obtained. The other tissues compartment was aerated with air mixed with 5% CO 2 . The reactor was operated for 30 min to test for leaks. A 1 mL sample of medium was taken at time ) 0.
The system was then dosed with naphthalene. Naphthalene stock was made by dissolving 50 mg of crystalline naphthalene in 1 mL of methanol, and 0.540 mL of the stock was injected into the other tissues beaker to obtain a 300 mg/mL concentration. Control cultures were not exposed to naphthalene or methanol; 1 mL medium samples were taken at hourly intervals for 4-6 h.
At the end of the runs, the lung and liver compartments were detached from the apparatus, and control bottles were removed from the incubator for analysis. Final medium samples were taken, and all medium was removed from the bottles. A lysis buffer of PBS plus 1% Triton X-100 was added to the cells, and the cells were lysed at 37°C for 2 h (17). Cell lysate was analyzed immediately for GSH content and the next day for intracellular LDH. Medium samples were analyzed for LDH.
Packed Bed Operating Protocol. The packed bed CCA (8) is configured analogously to the prototype with three separate compartments. The system was operated in an incubator at 37°C with 5% CO 2 in air and 90% relative humidity. Details of the design and operating procedure are provided in the companion paper (8) and summarized here. The lung and liver compartments were inoculated with cells grown to 80% confluence on microcarrier beads through the sample ports while medium was circulated through the reactor. Samples were taken at regular intervals and stored,and then intracellular LDH and GSH and medium LDH were measured.
Naphthalene dissolved in methanol was added via a glass needle and stainless steel syringe into the other tissues compartment. Control reactors were dosed with the equivalent amount of methanol.
Samples were prepared for intracellular GSH and LDH measurements by sonicating the cells on microcarrier beads in ice-cold PBS or ice-cold PBS with 10% Triton X-100. The same lysate was used for both measurements. For measurement of LDH in the extracellular medium, medium samples were taken and the assay was performed directly on these samples with no other preparation. All samples were kept on ice until the GSH assay was performed (immediately after sampling) and then refrigerated at 4°C until LDH assays were performed later the same day. Samples were taken in triplicate, and standard errors are shown.
PBPK Development. PBPK models have been developed to describe both CCA designs (prototype and packed bed) (3, 11, 12) . Both models are based on the schematic of a three-compartment PBPK, as shown in Figure 4 . The PBPK structure and kinetic parameters were the same for both models. The models were different in compartment residence times and number of cells to reflect the differences between the CCA designs. Model residence times are shown in Table 1 . The PBPKs were modified by changing various parameters (cytochrome P450 activity to that measured for H4IIE cells and residence times appropriate to the reactor configuration) and adding the formation of naphthoquinones to the mechanism to probe the basis for the different results from the two experimental systems. Appendix 1 details the additional equations necessary to estimate naphthoquinone formation. The rate of conversion of naphthol to naphthoquinone due to CYP450 activity was estimated to be 22 nmol/mg protein-min on the basis of ref 20.
Experimental Results
Prototype CCA Control Experiments. Experiments were conducted using the described prototype cell culture analogue configuration but altering the cell type in the compartments to compare the effects of kinetic and distribution changes to the results of the prototype experiments. That is, instead of lung-liver-other tissues arrangement, the following combinations were used: a lung-lung-other tissues arrangement, lung-blankother tissues arrangement, and a liver-blank-other tissues arrangement. These experiments were compared to the lung-liver-other tissues experiments by Sweeney (2, 11) . Results are shown in Table 2 .
Experiments were conducted with only one cell type in the reactor. To determine if the metabolizing cells in the liver (H4IIE cells) were actually responsible for producing the glutathione-depleting effect shown in the prototype experiments, a nonmetabolizing cell type was used in the liver compartment instead. Specifically, L2 cells were used in both compartments (a lung-lung experiment). Control cells were kept in flasks in the incubator, and the system was dosed with 300 mg/kg of naphthalene as described for the prototype experiments. After the 6 h experiment there was no intracellular GSH depletion in the L2 cells in the lung compartment, and an increase in intracellular GSH in the L2 cells of the liver compartment. LDH release in the CCA system was slightly higher than in control flasks maintained in the incubator but well below that in the H4IIE-L2 system (see 2, 11) .
To determine if the L2 cells in the lung compartment were responsible for producing the GSH depleting effect, the prototype reactor was operated with L2 cells in the lung compartment and no cells in the liver compartment, under the same conditions as previous prototype runs. This configuration resulted in no GSH depletion in the L2 cells in the lung compartment as compared to controls.
Because it is also possible that the H4IIE cells in the liver compartment produce metabolites that in turn affect the H4IIE cells in the liver compartment, the CCA was operated with H4IIE cells in the liver compartment and no cells in the lung compartment (liver-blank), under the same conditions as previous prototype experiments. Under these conditions the intracellular GSH of the H4IIE cells in the liver compartment did not differ from controls. These results support a hypothesis that a circulating reactive metabolite was generated in the liver compartment (H4IIE cells) that caused GSH depletion in the L2 cells.
Packed Bed CCA. Naphthalene dosing experiments were performed with the packed bed cell culture analogue bioreactor, varying the length of time of the experiment (and therefore sampling time intervals), concentration of naphthalene, and the administration of naphthalene. Experiments were repeated, and the results shown are for each individual experiment. In all cases shown, naphthalene-dosed and control reactors were run simultaneously. All experiments were repeated and both sets of results are shown. When error bars are shown, they indicate the standard error of three samples. Figure 5 shows results of reactor runs in serum-free medium, presented as percent of initial specific GSH, where specific GSH is GSH/LDH (intracellular LDH is indicative of cell number). GSH did not change significantly with time after dosing, and the experiment and control were very similar after dosing. There did appear to be a slight increase in specific GSH overall after dosing, but this is possibly due to factors other than naphthalene dosing.
Experiment duration, and time interval between samples were examined. Two total times were used, 2 or 6 h. In both experiments the same or similar number of samples were taken, so the sample interval differed. Sample number was limited because the sample volume was large relative to the total volume of the compartments. In the 6-h experiments the sample intervals are much larger (2 h), whereas in the 2-h experiments it was possible to sample much earlier after dosing. The 6-h experiments shown in Figure 5 include a 2-h adjustment time before dosing.
The 2-h runs also had a 2-h adjustment period before dosing, but samples were not taken during this period. Samples were taken immediately prior to dosing, at t ) 0 on the plots. Figure 6 shows the results of two 2-h experiments, expressed as GSH/LDH (intracellular LDH being an indicator of cell number). As described previously the dosed and control experiments are very similar at 2 and 4 h after dosing, and the change with time is also small, although there appears to be a slight increase in GSH/ LDH overall. The 2-h studies show agreement between dosed and control systems; however, in both cases the lung compartment shows a small drop in GSH/LDH 5-15 min after dosing. Also there is a more distinct increase in GSH/LDH over the initial measurement at the 2-h time point, and the controls increase to a higher level than the dosed.
Because naphthalene has low solubility in water, the principal constituent of cell culture medium, methanol is used as a solvent. Methanol does not affect the cells in static culture under similar doses (8) . Control reactors are dosed with the equivalent methanol used in naphthalene dosing. It is possible that the cells are responding to the methanol rather than the naphthalene or that they are responding to both substances and the difference in response to naphthalene is obscured by its response to methanol. To eliminate the effect of the methanol solvent, the CCA was operated with naphthalene dissolved in medium. Controls were undosed reactors. Results of repeated experiments are shown in Figure 7 . As seen with previous runs, there is no appreciable difference between the naphthalene-dosed CCA and the control. Naphthalene does not appear to affect the specific GSH (expressed as GSH/protein where protein is indicative of cell number) in the absence of methanol. In all of these experiments there was little difference between reactors dosed with naphthalene and nondosed controls.
PBPK Model Results
Packed Bed vs Prototype. PBPK model results of the packed-bed CCA configuration are compared to the PBPK model results of the prototype configuration. Figure 8 shows the response to naphthalene dosing of the packed bed PBPK compared to the response of the prototype PBPK. The difference between these two PBPKs is the physical structure of the apparatus. The packed bed PBPK models cells on microcarrier beads, and the PBPK prototype models cells as a monolayer, each taking into account the number of cells possible in such systems. Both cases use the same H4IIE and L2 cell characteristics (such as cell size), thermodynamic parameters, and kinetic parameters. To compare these CCA designs to whole animal PBPK response, cytochrome P450 levels consistent with primary cell cultures were used in baseline calculations. Lung GSH depletion is much slower in the prototype PBPK and does not reach a minimum in the time span of the run, where in the packed bed PBPK the lung GSH is predicted to deplete more quickly and reach a minimum level of depletion. In the liver, the depletion is more rapid in the packed bed and also rebounds more quickly than the prototype. To summarize, in both compartments the GSH is depleted more rapidly and to lower levels in the packed bed CCA than in the prototype. GSH rebound is evident only in the liver compartment of the packed bed CCA. In the 6-h duration of the CCA runs, no GSH rebound is shown by the model in the packed bed lung compartment or either compartments of the prototype.
The two models differ in compartment volumes, cell numbers, and the organ residence times. The circulating medium spends more time in the lung and liver compartments and less in the other tissues compartment. The biggest factor leading to more metabolism in the packed bed model compared to that in the prototype is the higher density of cells in the liver that is achieved with microcarrier beads.
Packed Bed vs Animal Residence Times. It is evident that there are significant differences between the PBPK for the packed bed model, which uses actual rat blood flow rates as a design basis, and the PBPK for the whole animal model, where the basis is the blood residence time in the organ, and flow rates are calculated from these. The flow resistance in the packed bed prevented reaching sufficiently high flow rates in the experimental system to achieve the actual residence times. A comparison is shown in Figure 9 . The whole animal model (a three-compartment PBPK) predicts much more metabolism in both lung and liver compartments, both in terms of extent and duration. Residence times in both compartments in the whole animal model are shorter, so more of the oxide produced in the liver will circulate, resulting in more GSH depletion in the lung. In fact this circulation is also possibly responsible for the extended GSH depletion in the liver. If primary cells could be used in the packed bed CCA, it would provide a reasonable representation of animal metabolism in the liver while underpredicting lung GSH depletion by 50%. On the basis of a combination of the results in Figures 8 and 9 , the packed bed CCA would better represent animal metabolism than the prototype CCA if authentic cells were available.
Kinetic Parameters. The above PBPK model of the CCA uses kinetic parameters estimated from primary cell fractions with physiological parameters representative of the CCA configuration. The cell types used in the CCA reactor are cell lines and differ from primary cells, which often have higher levels of metabolic capability. A PBPK model that is an exact replica of the CCA requires kinetic parameters that correspond to those cell types used in the CCA. Enzymes involved in the metabolism of naphthalene are cytochrome P450, which converts naphthalene into the enantiomeric naphthalene oxides; epoxide hydrolase, which catalyzes the formation of dihydrodiols from the reactive oxide metabolites; glutathione Stransferases, which catalyze the conjugation of the oxides to glutathione; and the rate of nonenzymatic formation of 1-naphthol. Obtaining these parameters requires extensive experimentation that has not yet been completed, but some data have been obtained from S. Sugisaki (data not published). Enzyme activities were (3) . No attempts to identify the presence of the third isozyme, cytochrome P450IIF, in H4IIE cultures have been found in the literature nor conducted in this laboratory. Table 3 summarizes the activities of cytochrome P450IA1 in the cell types used in the CCA reactor (measured in this laboratory and found in the literature) as compared to isolated rat hepatocyte fractions and also the values used in the PBPK. The differences between the rat hepatocyte cytochrome P450IA1 activity and the activity in the H4IIE cells used in the liver compartment of the CCA are 100-fold. The kinetic parameters used in the original PBPK are based on rat hepatocyte data and are also shown in Table 3 . These values are much higher than the activities of comparable enzymes in the H4IIE cells. The two values shown are for the stereospecific catalysis of naphthalene to the two enantiomers of naphthalene oxide (5) .
The PBPK models of the two CCAs were run with a lower V max to reflect the measured cytochrome P450 activity in H4IIE cells. A comparison of results with two cytochrome P450IA1 kinetic parameters from primary cells (12) and H4IIE are shown in Figure 10 for both types of reactor.
With the modified kinetic parameters, which are representative of the cells used in the CCA, the response to naphthalene is attenuated in both designs. The difference in hepatocyte kinetic parameters and H4IIE kinetic parameters affects the packed bed case more dramatically than the prototype, as this design has more metabolism than the prototype.
The responses of the two CCA designs (packed bed vs prototype) with lowered P450 values are compared to each other in Figure 11 . There is still more GSH depletion in the packed bed reactor than in the prototype, although the difference is much less than with the primary cell parameters.
Naphthol Toxicity. Recently several groups have reported that in addition to naphthalene epoxides, naphthoquinones are reactive metabolites of naphthalene that bind to Clara cell proteins, resulting in toxicity (18, 19) . Quinones are electrophilic agents with reactivity toward nucleophiles. Naphthol is formed by nonenzymatic rearrangement of naphthalene epoxides, and Zheng et al. (21) have proposed a mechanism of naphthoquinone formation from the 1-naphthol species based on enzymatic conversion by cytochrome p450s. The unmodified PBPK model takes naphthalene metabolism only to the level of 1-naphthol formation, so it can only be used to determine how the reactor design affects the formation of the quinone precursor, naphthol. If the naphthoquinones are toxic metabolites that bind to proteins, differences in reactor responses may be linked to differences in naphthoquinone formation. Figure 12 shows the predicted formation of naphthol in the lung and liver in the packed bed PBPK as compared to the prototype PBPK. Naphthol formation in the lung and liver are much higher in the prototype CCA than in the packed bed. However, in the other tissues compartment, there is more naphthol formation in the packed bed PBPK.
Quinone Formation. The PBPK models for the packed bed reactor and the prototype reactor were extended to include the formation of naphthoquinone from naphthol and the subsequent binding of the quinones to proteins. These quinones are formed in the liver through a cytochrome P450 mediated reaction and circulate throughout the CCA. Binding can occur in all compartments. Kinetic parameters of quinone formation are based on the cytochrome P450 activity in rat liver microsomes used in a study of 1-naphthol toxicity (20) , and binding parameters were the same as those used for naphthalene epoxide binding in the lung, liver, and medium in the original PBPK (12) .
Results of quinone formation in the two PBPK models are compared in Figure 13 . In both lung and liver compartments the amount of quinone is much higher in the prototype than in the packed bed model. This result is paralleled by a higher level of bound quinones in both compartments, as shown in Figure 14 .
As the cytochrome P450 is likely to be lower in the H4IIE cells used in the liver compartment than in rat liver microsomes, the sensitivity of quinone binding to cytochrome P450 levels was examined. Figure 15 indicates the amount of bound quinone expected with a one 100-fold decrease in the cytochrome P450 catalyzing quinone formation from naphthol. The same trends are seen with more bound quinones formation in lung and liver compartments of the prototype than in the packed bed model, but the overall amounts of bound quinones are lower than with the higher cytochrome P450 levels. The predicted level of bound quinones in the prototype system is about 100-fold higher than in the packed bed system.
Discussion
Prototype Runs. The GSH depletion in the L2 cells of the lung compartment of the prototype after naphthalene dosing supports the hypothesis that reactive metabolites are produced by H4IIE cells in the liver compartment and circulate to the lung compartment where they can conjugate to L2 cell GSH. The L2 cells do not have the metabolizing enzyme necessary to produce naphthalene metabolites, whereas the H4IIE cells do. The metabolites are not directly measured but are inferred by the decrease in intracellular glutathione. Further studies were undertaken to attempt to confirm this hypothesis. A set of experiments was done using the same protocol but changing either the metabolic capabilities or the distribution of medium of the prototype CCA (e.g., lung-lung, liver-blank, blank-lung combinations). In these experiments there was no depletion of GSH in any of the cell types in any compartment. The only configuration that did produce a GSH depletion was lung-liver-other tissues, with L2 cells in the lung and H4IIE cells in the liver. These observations are consistent with the hypothesis that the H4IIE cells in the liver compartment produce a metabolite from naphthalene that circulates to the lung compartment and affects the lung cells (2) . The release of LDH into the medium, which is indicative of cell death, was greater in CCA prototype dosing experiments than in nondosed CCA experiments. This result would indicate that the metabolizing reactor configuration increases cell death over the nonmetabolizing and modified circulation systems, presumably as a result of formation of circulating naphthalene reactive metabolites formed in the liver.
Packed Bed CCA Runs. In vivo studies on mice show that the glutathione depletion reaches a minimum between 2 and 4 h after dosing (6), but actual animal death happens approximately 6 h later (22) . The times chosen to study were based on these numbers, but due to limitations in sampling, where the samples had to be relatively large compared to the overall cell content, a limited number of sample times were possible for each experiment. In the initial 6-h experiments, a 2-h time period was permitted between dosing and the first sample and 2 h between subsequent samples. No response was observed, and it was postulated that glutathione depletion was occurring prior to the first sample. To capture earlier effects, shorter length runs were conducted where samples were taken shortly after dosing and at short intervals thereafter. The total length of time of these experiments was 2 h.
The 2-h experiment results shown in Figure 6 were conducted under the same conditions as the longer experiment shown in Figure 5 . They are consistent in that the lung chamber cells do show a small drop in GSH at 5-15 min after sampling, and there is a large rebound in GSH at the 2-h point. The liver cells show only the increase in GSH at the 2-h point. In all cases, GSH in the control packed bed CCA rebounds to a higher level than the naphthalene-dosed packed bed CCA.
In the prototype CCA experiments and most of the experiments conducted with the packed bed reactor, naphthalene was administered to the reactor in methanol as a carrier, and an equivalent amount of methanol was administered to the control. Similar results were seen between the dosed and control reactors, so the effect of methanol on the glutathione status of the cells was considered. In static studies the effect of methanol, and methanol plus naphthalene, on H4IIE and L2 cells was the same as no dose controls (13) .
Experiments were conducted where naphthalene was administered without being dissolved in methanol but was finely crushed and administered in medium in a supersaturated state. Controls to these experiments were reactor runs without dosing of any kind. In both dosed and nondosed control cases, shown in Figure 7 , there is an increase in GSH after 2 h, although not to the same extent seen in the cases where naphthalene is dissolved in methanol. Again there is no significant difference seen between the controls and experiment. Naphthalene does not have an effect on the cells in this case, so it appears that methanol is not interfering with results of the previous studies.
Differences in response to naphthalene dosing were seen between the prototype reactor and the packed bed reactor. The prototype showed a depletion of glutathione in the lung compartment that was not evident in no-dose controls or controls with only one compartment or cell type (2) . This result supported the hypothesis that naphthalene metabolites were being formed in the liver compartment, which then could circulate to the lung compartment and affect lung cells. These metabolites were not directly measured. However, the packed bed reactor design did not show the same response. The packed bed experiments indicate very little difference between naphthalene-dosed reactors and controls.
Quick (12) developed PBPK models of the two CCA designs that are used here as a tool to explain the differences in responses observed between the two reactor designs. The models differ in cell number and compartment volume while maintaining the same kinetic parameters. The PBPK has been used here to test scenarios that could explain the results of naphthalene dosing on the cell culture analogue reactor. Specifically, differences in distribution parameters, kinetic parameters (obtained from primary cell fractions compared to those obtained from the cell lines used in the reactor) and toxic mechanisms were input to the PBPK and compared to CCA results. PBPK models of both CCA designs show that the cytochrome P450 activity affects the response greatly, as would be expected. GSH is depleted to a small extent in both compartments of either CCA design when the kinetic parameters are based on the measured activity of P450IA1 in the H4IIE cells although the depletion is greater in the packed bed CCA. The cytochrome P450IA1 measured in the H4IIE cells is about 4-fold less than reported in the literature for this cell line (19) . Changes in H4IIE enzyme activity during long periods of storage and subculture are possible, but since cytochrome P450IA1 was not measured in the H4IIE cells used in the prototype it is not possible to determine if the H4IIE P450IA1 activity had changed. Even a 4-fold change in activity would not provide a basis to explain the difference in observed response of the two CCA systems.
The production of 1-naphthol was calculated to be much greater in the prototype PBPK than in the packed bed PBPK, so if 1-naphthol is involved in the toxicity of naphthalene the differences in GSH depletion between the two reactor designs might be attributed to the extent of naphthol production. Evidence in the literature indicates that bioactivated 1-naphthol is more cytotoxic to mononuclear leukocytes than bioactivated naphthalene, and the naphthoquinone metabolites of naphthol depleted GSH to 1% of control levels (20) . Wilson et al. also found that mononuclear leukocytes treated with 1,2-naphthoquinones and 1,4-naphthoquinones showed a concentration-dependent increase in cell death, whereas naphthalene 1,2-epoxide was not cytotoxic at comparable concentrations. Other evidence shows that naphthoquinone metabolites bind to Clara cell proteins (21) .
Results of the two PBPKs with quinone formation and quinone binding to proteins show that both levels are more than 2 orders of magnitude higher in the prototype PBPK than in the packed bed PBPK. Naphthol formation is higher in the prototype because of the higher residence time in the liver compartment. The increased residence time allows more time for the nonenzymatic conversion of naphthalene epoxides into naphthol and the subsequent conversion through P450IA1 into quinones. If the quinone metabolites are indeed binding to GSH in the actual CCAs this is the most likely explanation for the GSH depletion in the prototype that is not evident in the packed bed CCA.
The above discussion indicates a strength of the combined CCA-PBPK approach to the investigation of toxic mechanism. On the basis of earlier experimentation (2) and literature (7), the assumed toxic mechanism was that naphthalene epoxides bound to proteins, but differences in results from the two different CCAs brought that assumption into question. Changes in naphthalene metabolism in the PBPK model (the addition of quinone formation and binding) give model results that are more consistent with experimental results. These results provide support for the plausibility of the hypothesis that naphthoquinones are important metabolites involved in naphthalene toxicity. Also, this approach demonstrates that the PBPK used in conjunction with the CCA provides an important tool to probe toxicological mechanisms.
The primary difference between the two CCA designs is that the liquid residence times were different. Longer liver residence times allow more time for the nonenzymatic conversion of naphthalene oxides into 1-naphthol and the enzymatic machinery to convert 1-naphthol into quinones, which can then circulate. It is perhaps ironic that the packed bed CCA, which is more physiologically realistic, shows less response than the prototype CCA. Nonetheless, the application of the PBPK to each CCA design allows the mechanistic interpretation of the experimental results.
For the PBPK model to be more useful, the full range of kinetic parameters needs to be determined for the actual cells used in the model. These include rates for the formation of naphthalene epoxides, dihydrodiol, 1-naphthol, and glutathione conjugates and the formation of naphthoquinones from 1-naphthol. The model should be extended to include naphthoquinone conjugation to GSH. 
